Ligand Pharmaceuticals reported $2.67 in EPS Earnings Per Share for its fiscal quarter ending in September of 2026.


Fiscal Calendar Actual Consensus Previous Date
FY2026Q3 Sep/2026 2.67 2.54 3.09 Oct/29
FY2026Q2 Jun/2026 2.37 1.95 1.60 Aug/06
FY2026Q1 Mar/2026 1.63 1.82 1.33 May/07
FY2025Q4 Dec/2025 2.02 1.49 1.27 Feb/26
FY2025Q3 Sep/2025 3.09 1.93 1.84 Nov/06




Eps Change Date
Agenus USD 1.02 1.32 Mar/2026
Amgen USD 6.45 0.16 Sep/2026
Anika Therapeutics USD 0.13 0.35 Dec/2025
Arrowhead Research USD -5.11 3.75 Sep/2026
Baxter International USD 0.58 0.02 Sep/2026
Bristol-Myers Squibb USD 1.35 0.69 Sep/2026
Eli Lilly USD 7.48 0.9 Sep/2026
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
Enviri Corporation USD -1.02 0.92 Dec/2025
Gilead Sciences USD 2.55 9.3 Sep/2026
GlaxoSmithKline GBP 0.55 0.04 Sep/2026
Glaxosmithkline GBP 0.76 0.14 Sep/2026
Heron Therapeutics USD -0.02 0.02 Dec/2025
Insmed USD -0.46 0.4 Sep/2026
Intrexon USD -0.1 0.03 Jun/2024
Ionis Pharmaceuticals USD 0.66 1.35 Sep/2026
Karyopharm Therapeutics USD -1.02 1.2 Mar/2026
Ligand Pharmaceuticals USD 2.67 0.3 Sep/2026
MacroGenics USD 0.31 0.89 Jun/2026
Merck USD 2.49 2.62 Sep/2026
Pacira USD 0.7 0.03 Sep/2026
Pfizer USD 0.87 0.1 Sep/2026
Rigel Pharmaceuticals USD 0.7 0.76 Sep/2024
Sangamo BioSciences USD -0.18 0.1 Jun/2024
Veracyte USD 0.51 0.03 Sep/2026